Sponsored by BioAdvance, the Life Sciences Greenhouse of Central Pennsylvania, and Sonnenschein Venture Technology

As a new addition for this year, Biotech 2008 will feature Partnering sessions on Monday, November 10, 2008 from 9:00 a.m. - 3:00 p.m.  Fourteen companies will be chosen to give presentations as part of these three sessions.  These companies will provide an overview of their company and technologies to potential partners, investors, and fellow industry professionals. 

Don't miss this opportunity to hear more about some of the innovative bioscience companies in the Mid-Atlantic region. 

Session I - 9:00 a.m. - 10:15 a.m.

Promedior, Inc. is a product-focused biopharmaceutical company developing novel therapeutics for the treatment of fibrotic diseases.  It is estimated that 45% of all deaths are a result of tissue fibrosis yet there are currently no approved therapies.  Promedior is pioneering a new approach to treat this devastating class of diseases which relies on the fundamental role of the innate immune system in regulating the scarring and remodeling process.  The company is beginning clinical development of its first product candidate in Q1'09. 

KNOPP NEUROSCIENCES is a drug discovery and development company delivering breakthrough treatments in neurological disorders. Knopp's lead candidate, KNS-760704, is a mitochondrially targeted small molecule entering Phase 3 in ALS. KNS-760704 exhibits potent cytoprotective action and ideal pharmaceutical properties: high oral bioavailability, rapid absorption, and active transport into the brain. The compound has previously demonstrated dose-dependent effects in reducing the rate of disease progression in open-label studies under the research IND of an academic sponsor.

INRange's product, EMMA^®, is the first and only medical device cleared by the FDA which may be used to remotely manage a patient's medications.  EMMA^® is designed for patient self-load and in-home use.  It is remotely programmed, utilizing broadband wireless communications, by a pharmacist from their office. 

EMMA^® represents a fundamental improvement to the cost and delivery of outpatient healthcare.  It was designed to reduce medication errors, improve adherence, control narcotics and improve patient safety.

Melior Discovery has developed an innovative, cost effective strategy to uncover new uses for drug candidates by using a unique in vivo screening platform (theraTRACE^®).   Melior has leveraged this proprietary screening platform to develop a business model that balances the development of its internal pipeline of proprietary drugs with research collaborations that generate a growing revenue stream.  In this regard, Melior has quickly established partnerships with several of the world's leading pharmaceutical companies.

Tengion, a clinical stage biotechnology company, focuses on developing, manufacturing and commercializing human neo organs and neo-tissues using the Autologous Organ Regeneration PlatformTM. Tengion uses biocompatible materials and a patient's own (autologous) cells to create a functional neo-organ that is designed to catalyze the body's innate ability to regenerate. The Company's lead product, the Neo-Bladder AugmentTM, is currently in late Phase 2 clinical trials in the United States.  The Company expects to enter Phase 2 clinical trials in 2009 with the Neo-Bladder ConduitTM for patients whose bladders are removed for conditions such as bladder cancer.

NuPathe Inc. is a specialty pharmaceutical company developing innovative therapeutic products for the treatment of neurological and psychiatric diseases. NuPathe's mission is to identify and address the needs of patients, their families, and health care professionals.

NuPathe accomplishes its mission by licensing or acquiring product opportunities that can have an immediate and significant impact on disease treatment and management.  NuPathe is currently developing products to treat migraine (Phase III) and Parkinson's disease (preclinical).

ALung Technologies, Inc. (the "Company") is commercializing the Hemolung System, a disruptive and transformational new therapy that replaces the respirator in the ICU, while providing a full payback to the hospital with the first two (2) weeks of use.  The Hemolung can be used in 600,000 patients annually in the U.S., representing a $2.3 billion dollar market.  The company has 7 issued patents with broad method protection and a seasoned management team with over 80 years in combined experience in respiratory and extracorporeal therapies.  European sales are expected six months after full funding, and FDA clearance is expected 24 months after funding.  Market adoption of the Hemolung will be driven by the complete avoidance of intubation and significant reduction in hospital costs.

NexMed (NEXM:  Nasdaq) leverages its proprietary NexACT^â skin permeation technology to produce new, biodegradable, non-toxic topical formulations of existing drugs.  The pipeline addresses nail fungus, erectile dysfunction, female sexual arousal disorder (FSAD), and psoriasis.  NexMed offers pharmaceutical companies, like partners Novartis and Warner Chilcott, Ltd., the opportunity to incorporate NexACT^â into existing drugs, allowing R&D savings and the development of new, patient-friendly transdermal products with extend brand equity and patent life spans.  NexMed is pursuing a FSAD co-development partnership.

Celldex Therapeutics is an integrated biopharmaceutical company that applies its comprehensive Precision Targeted Immunotherapy Platform to generate a pipeline of candidates to treat cancer and other difficult-to-treat diseases. Celldex's immunotherapy platform includes a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immuno-modulators to create novel disease-specific drug candidates. For more information, please visit www.celldextherapeutics.com.

EKR Therapeutics, a specialty pharmaceutical company dedicated to improving outcomes and patient quality-of-life in the acute-care hospital setting, focuses on identifying, acquiring, and fostering the growth of novel products severing the needs of this important healthcare segment. Founded in late 2005, EKR has brought together a highly cohesive team of pharmaceutical professionals, and the Company has grown from a start-up situation with one product in 2006 into a profitable organization with four commercial products by early 2008.

Vicus Therapeutics, a privately-held biopharmaceutical company focused on oncology supportive care drugs, recently completed a multi-center, randomized, open-label, controlled, Phase 2 trial of VT-122 in 37 weight-losing cancer cachexia subjects with advanced lung cancer not on chemotherapy.  Of subjects treated with VT-122,  44 percent showed a clinically meaningful gain of more than 5 percent in lean-body-mass; no subjects on best supportive care arm showed any gain (p value <0 .01). No treatment-related serious adverse events were reported.

The mission of Neurotez is to become leaders in biotechnology drugs for CNS, using biochemistry, molecular & cell biology and in vivo models to identify potential biopharmaceuticals and a novel screening procedure identifying protein candidates amenable to therapeutic manipulation. The company's lead biopharmaceutical is Leptin, an adipocyte hormone thought to be controlling energy homeostasis, is proposed for replacement therapy in elderly and Alzheimer's disease patients (patent pending). Neurotez has also identified a novel protein-protein interaction in a subset of familial, early onset AD.

Lux Biosciences is a clinical stage biotechnology company specialized in the field of ophthalmic diseases. We are developing novel medications to treat the underlying causes of ophthalmic diseases and alleviate their symptoms, and if approved by regulatory authorities, we plan to commercialize these products. With two first-in-class products currently in Phase 3 clinical development and several innovative, highly promising earlier stage projects, we have made significant progress towards building a revenue-generating, high-growth, and sustainable ophthalmic company.

DOR BioPharma, Inc. (OTCBB: DORB) is a late-stage biopharmaceutical company developing products to treat life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines for certain bioterrorism agents. DOR's lead product, orBec^® (oral beclomethasone dipropionate or BDP), is a potent, locally acting corticosteroid being developed for the treatment of acute gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of hematopoietic cell transplantation (confirmatory Phase 3 study planned for 1H09).